vTv Therapeutics Randomizes First Participant in Phase 2a Cadisegliatin Study
vTv Therapeutics said it randomized the first participant in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin.
vTv Therapeutics said it randomized the first participant in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin.